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ABSTRACT
Objective: Following a revision of the Swiss Federal Health Insurance Act, the regional hospital planning structure was modified
and the hospital financing organized at a national level with the use of diagnosis related groups (SwissDRGs). The aim of
this observational study was to determine in an independent way the initial impact of these changes on the quality of hospital
treatment, with patients hospitalized for Acute Myocardial Infarction (AMI) being the chosen study group.
Methods: We used prospective data from a Swiss clinical registry for AMI. The quality was measured based on the adherence
to 10 evidence-based performance indicators for AMI treatment, and on the evaluation of in-hospital outcomes (mortality,
complications, length of hospital stay [LOS]) globally and for seven pre-defined vulnerable subgroups. The study compared
patient-based data before (2011) and after (2012) the implementation of the reform.
Results: The study included 33 matched hospitals, and compared the AMI treatment of 2,491 patients in 2011 (before) and 2,544
in 2012 (after the hospital reform). No significant changes in the evidence-based performance indicators were observed, but an on
average one day reduction in the LOS and worse outcomes in one of the pre-defined group of patients were found. The issue of
how the clinical team achieved these results was not directly explored due to the underlying registry’s unalterable structure.
Conclusions: One year after the implementation of a new hospital financing system in Switzerland, the quality of treatment
delivered to patients hospitalized for AMI was maintained overall. The worse in-hospital mortality in one pre-defined vulnerable
subgroup could reflect the emergence of difficulties for clinical teams to cope with patients demanding extra care and time.
Further investigation is warranted.
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1. INTRODUCTION
Healthcare systems differ worldwide but they all share the
common aims of high quality and cost containment, which
in turn leads to a need for reforms and for an increased ac-
countability to monitor and evaluate health care changes and
disease management. The recent revision of the Swiss Fed-
eral Health Insurance Act was planned to both contain hos-
pital costs and guarantee hospital healthcare quality, whilst
respecting the three main principles of effectiveness, ade-
quacy and economical efficiency, as laid down by the law.[1]
Switzerland was therefore a good proxy for the evaluation of
healthcare quality under cost constraints.
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Table 1. Reform of hospital financing in Switzerland[1]
 
 
Common features of Swiss hospital financing before and after the reform implementation  
    •  Universal basic health insurance (UHI) compulsory for each Swiss resident, federal competence. 
    •  Multiple competitive Swiss health insurers for UHI.  
    •  Private complementary insurers. 
    •  Cantonal (i.e. regional) competence for healthcare planning.  
    •  No free choice of doctor in hospital. 
    •  Health services not covered by UHI: payments by patients and private insurers. 
Main UHI financial aspects before January 2012 Main UHI financial aspects from January 2012 
Cantonal planning  
 Cantonal competence. 
 Establishment of a cantonal list of public and subsidized hospitals  
eligible for cost reimbursement.   
 Choice of hospital: free choice limited to hospitals enlisted on the 
cantonal list of the resident. 
 Cost allocation: 
          ○  Cantonal listed hospitals: Minimum of 50% at cantonal level,  
               remaining cost paid by UHI.   
          ○  Cantonal non-listed hospitals: payments by patients and private 
               insurers. 
          ○  Hospitals in other cantons: full payments by patients and private 
              insurers (except for extra-cantonal hospitals enlisted in the  
              cantonal list and in a few medically justified exceptions). 
 
• Cantonal competence, but economics, infrastructure and quality 
standards for hospital selection are defined at federal level. 
• The cantonal list of eligible institutions for cost reimbursement  
includes not only public and subsidized hospitals, but also private 
hospitals and potentially hospitals from other cantons. 
• Choice of hospital under UHI: free choice for the whole of  
Switzerland, amongst the list of indexed hospitals. 
    •  Cost allocation: 
          ○  Cantonal listed hospitals: Minimum of 55% at cantonal level, 
              maximum of 45 % for UHI.   
          ○  Cantonal non-listed hospitals: payments by patients and private 
              insurers or if they have signed a contract with UHI, UHI  
              contributes up to 45%.  
          ○  Listed hospitals in other cantons: reimbursement based on the 
              residential cantonal prices.  Potential surcharges paid by  
              patients and private insurers.  
Payment model for health services and structure   
 Collectively negotiated between hospitals and health insurers and 
approved by the respective canton at individual cantonal level. 
 Daily price, fee-for-services, AP-DRGs, or mixes of them.  
 Infrastructure investments managed separately from health services  
payment. 
 
 Collectively negotiated between hospitals and health insurers and 
approved at national level. 
 Based on Diagnosis Related Groups (SwissDRGs) for somatic 
acute care.  
 SwissDRGs’ national cost-weights applied to hospital basis price.  
 Infrastructure investments included in SwissDRGs. 
Challenges  
 Discriminatory cantonal allocation of costs for citizens with 
complementary private insurances compared to citizens with UHI 
only (judicial judgment).  
 Outside of a few exceptions, no free country-wide choice of hospital. 
 Limited availability of national standards to compare hospital 
services between cantons. 
 Limited cost transparency reported at insurers’ level.  
 Inadequate dual financing of hospital investment and services at 
cantonal level.  
 Difficulties in containing hospital costs.  
 Who pays the costs in excess of SwissDRGs reimbursement rates? 
Not the insurers (max 45%), therefore the institutions’ owner? 
Canton? Need to close or restructure hospitals?  
 Threat to quality of health services and professional practice due to 
cost pressure from SwissDRGs. 
 Risk of under-investment.  
 Insurers able to challenge SwissDRGs coding and reimbursement 
levels, potentially delaying payment to hospitals. 
 Need to establish evidence of improved hospital economics, access 
and quality.   
 
The legal changes in Switzerland were implemented in 2012
and involved two sets of measures: A new cantonal hospital
planning and the introduction of a payment model based
on national diagnosis related groups (SwissDRGs). Table 1
summarizes the main features of the Swiss universal health
insurance (UHI) for hospitals and the modifications due to
the hospital financing reform. Some cantons in Switzer-
land have been working with DRGs (APDRGs) before 2012.
SwissDRGs, however, are based on an adapted version of the
German DRGs, which were considered to be very detailed,
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with a high level of precision for comorbidities and case
severity. Furthermore, as Switzerland is a small country with
German being the most widely spoken language, it was more
cost effective to take over the existing field-tested German
system.
The intent of the national harmonization was to compare and
control costs while guaranteeing health care quality, but to
date no evidence has been provided to support this claim.
There is as yet no national center for health care quality in
Switzerland and no independent program to assess the im-
pact of governmental health care reforms on hospital clinical
pathways. Swiss health care professionals were questioning
the new hospital policies, which could lead to a reduction in
the quantity of care for a standard case, to premature patient
discharges, and a decrease in the quality of hospital treatment.
Furthermore, patients requiring more intensive care could be
the most vulnerable.
The aim of this study was to assess the quality of a routine
hospital treatment, with independently recorded evidence-
based indicators and outcomes, in a comparative study before
and after the introduction of this Swiss national reform. The
results were also contributing to a multi-disciplinary project
assessing the impact of the reform on patient care and pro-
fessional practice.[2]
2. METHODS
The study was performed in order to collect prospectively
the data from the period before the implementation of the
reform, and used comparable indicators before and after the
changes. Moreover, the study design had to integrate the
constraints of the absence of a control group and the funding
period limited to 3 years.
2.1 Research strategy
The first step was to identify the agents concerned by the new
reimbursement policy and to define the types of measure-
ment.[3] Hospitals were the agents, and the measurement was
based on the implementation of evidence-based recommen-
dations for patients for a given disease. There are many ways
of measuring healthcare quality;[4] coded administrative data
and Inpatient Quality Indicators (IQI) are currently used,[5]
but they are linked to the coding guidelines and regulations of
the DRGs themselves,[6] with a possible self-preference bias.
In addition, the importance of an independent evaluation of
government-led reforms has been emphasized.[7] Thus, these
administrative data and IQI were not considered suitable for
this study.
The decision was thus to develop a quality measurement
based on evidence-based recommendations and observational
data in the field of acute myocardial infarction (AMI). First,
coronary artery disease is associated with a high burden
of disease and benefits from long-standing international re-
search and guidelines.[8] These evidence-based recommen-
dations highlight critical clinical care processes to ensure
quality in the treatment of AMI patients.[9] Second, adher-
ence to evidence-based recommendations can be measured
with observational data,[10] and clinical registries are exam-
ples of observational data supporting quality improvement
for a clinical condition, diagnostic, procedure or therapy.[11]
Third, there was an ongoing clinical registry for AMI in
Switzerland, registered at ClinicalTrials.gov and approved
by the Supra-Regional Ethics Committee for Clinical Studies,
the Swiss Board for Data Security, and the Cantonal Ethics
Commissions.[12]
2.2 Access to data and cooperation process
An agreement was signed at the beginning of 2011 with the
registry steering committee for the 3-year research period.
It permitted the secondary use of registry data for the years
2010, 2011 and 2012, but not an alteration of the primary
structure or sampling design of the registry itself. The par-
ticipating hospitals owned the data and data could not be
disclosed to other parties or published without prior consent
of the steering committee. It was agreed that registry data
were strictly confidential and that hospital names had to re-
main anonymous. Patient data were already de-identified in
the registry.
The presence of the study researcher in the registry data cen-
ter allowed an in-depth understanding of the production and
use of the registry data, and has thus facilitated transparency
and trust. The analysis of data developed in the study was
different from the registry’s usual analyses. In the registry,
the analysis took place on the basis of patient cases; matching
hospitals over the years was not required. In our study, the
matching units were the hospitals and as a consequence, pa-
tients from hospitals, which entered or left the registry in one
of the 2-year periods of study, were excluded. Furthermore
our study considered performance indicators with different
appropriate denominators. The registry analysis concerned a
larger and expandable number of variables and could include
data from several previous years. Despite these different
approaches to clinical data, the cooperation process led the
registry’s steering committee to support study disclosure.
2.3 Development of the measurements based on
evidence-based recommendations
Our study drew on international evidence-based recommen-
dations for AMI treatment with predominant class and level
of evidence IA or IB.[13–19] The 2010 retrospective registry
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data were used to adjust the measurement set to the exist-
ing registry structure. In 2010, 2275 AMI patients were
included in the registry by 39 hospitals and amongst them
9 had a round the clock catheter laboratory (CathLab) ser-
vice available. Some possible indicators were not developed
because adequate variables were not at that time collected
in the registry (e.g. initial heparin dose, adult smoking ces-
sation advice) or not systematically controlled (e.g. high
technology interventions for coronary vessels).
Other performance indicators were disregarded because of
missing or implausible data at a rate ≥ 5%: these were
mainly time indicators such as time from symptom onset to
hospital admission in patients transferred from/to hospitals
not participating in the registry, or in NSTEMI patients (with-
out ST elevation at the initial ECG) presenting usually with
a less straightforward diagnosis of AMI. For the purpose of
transparency, delays from symptom onset to hospital admis-
sion are shown as baseline characteristics, but not used as
performance indicators.
Vital signs at admission are also reported as baseline charac-
teristics only, because these data were not audited nor linked
to documented clinical shock. Only resuscitation prior to
admission was a controlled reported item. Risk factors were
identified from the anamnesis section of the questionnaire.
For instance a diagnosis of diabetes was identified from the
data reported under the headings Charlson index, risk factors
and regular medical treatment. Missing data exceeded 5%
for some items such as smoking habits, body mass index or
dyslipidemia, and was distributed unequally across hospitals
with no possibility to adjust them with a proper weighting.
These variables are shown as descriptive baseline but cannot
be used for group comparison. For the selected variables
to be reported and used as indicators, the measurement set
retained for the study had to achieve a rate of less than 3%
missing or implausible data from each participating hospital.
2.4 Measurement set description
The set combines ten performance indicators of adherence
to evidence-based recommendations, in-hospital outcomes
and an evaluation of access to care for pre-defined patient
subgroups. Table 2 details the measurement set.
In this study, primary percutaneous coronary intervention
(PPCI) refers to balloon angioplasty, with or without stent-
ing, undertaken as the primary reperfusion strategy for AMI
without previous or concomitant thrombolytic therapy and
performed within 24 hours following hospital admission.
Left ventricular systolic dysfunction was defined as the left
ventricular ejection fraction < 50% measured by angiography
or < 40% measured by cardiac echography.
In hospital outcomes included all-cause mortality, major ad-
verse cerebrovascular and cardiac events (MACCE), and the
length of hospital stay (LOS) measured in days: median,
(IQR 25th and 75th percentiles). Moreover, the following
seven subgroups were defined a priori as vulnerable because
they represent patients, who may have had a less straightfor-
ward diagnosis, required more intensive care or where delays
to hospital admission may have been more frequent. These
are: advanced age over 75 years,[20] female gender,[21] AMI
related cardiac insufficiency at admission defined with Killip
classes 3 or 4,[22] existence of comorbidities measured by the
Charlson comorbidities index (CCI) and more specifically
histories of diabetes or renal insufficiency.[23] We added the
socio-economic factor “basic insurance coverage only” for
patients only covered with the UHI (Universal Health Insur-
ance), additional private and semi-private insurances only
being paid by wealthier patients.
2.5 Implementation of the before and after study
The measurement set was applied to prospectively collected
data to compare the quality of treatment delivered to AMI
patients before (2011) and after (2012) the hospital payment
changes. The study included all patients from the national
clinical registry i.e. AMI patients hospitalized within the
first 24 hours of symptoms onset, and defined as STEMI or
NSTEMI by characteristic symptoms and/or ECG changes,
and cardiac marker elevation. Moreover as we wanted to
match hospitals before and after the reform, only patients
included by the hospitals that participated in the registry in
both years 2011 and 2012 were considered for the analysis.
We considered patient-based data in preference to admission-
based data; patient-based data follow patients across hospi-
tals and exclude double counting the same patient in the case
of hospital transfer.
2.6 Statistical analysis
Data are presented as a proportion of valid cases for discrete
variables, as means ± 1 standard deviation for normally dis-
tributed continuous variables and as medians with IQR (25%
and 75% percentiles) for non-normally distributed continu-
ous variables. Each individual adherence rate to guidelines
was calculated as a performance ratio of valid cases over eligi-
ble patients for the indicator. Comparisons before (2011) and
after (2012) concerned independent patients from matched
hospitals, and were compared using the Student’s two-tailed
unpaired t test for continuous normally distributed variables,
the Mann-Whitney U test for continuous non-normally dis-
tributed variables and the Pearson chi square test for categor-
ical variables. A probability value of < .05 was considered
significant.
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Table 2. Measurement set for patients hospitalized within 24 hours of acute myocardial infarction
 
 
Measure Name Eligible patients* Measure type 
A. Adherence rate to evidence-based recommendations in %  
1. Immediate triple therapy (ASA, P2Y12, AC) Alive in the first 24h Treatment 
2. Primary PCI performed: PPCI All Treatment, diagnosis 
3. Evaluation of LVEF (with angiography or 
echography) 
Alive at discharge Intermediate outcome,  diagnosis 
4. DAPT  (ASA, P2Y12) at discharge Alive at discharge Treatment 
5. Beta-blocker at discharge Alive at discharge Treatment 
6. Statins at discharge Alive at discharge Treatment 
7. ACEI or ARB for LVSD, at discharge Alive at discharge and LVSD Treatment 
8. Cardiac rehabilitation patient referral Alive at discharge and no transfer to other hospitals or 
nursing homes 
Patient education 
9. Door-to-balloon time ≤ 90 minutes STEMI, PPCI, no symptoms onset in hospital, 
no transfer from/to non participanting registry hospitals 
Treatment, process 
10. Time to reperfusion ≤ 12 hours STEMI, PPCI, no symptoms onset in hospital, 
no transfer from/to non participanting registry hospitals 
Treatment, process 
B. In-hospital outcomes   
1. All cause mortality, adjusted All  Outcome 
2. MACCE, adjusted  All Composite outcome 
3. Length of hospital stay, days (median, IQR) All Process, outcome 
C. Access to care/clinically vulnerable patients   
1. Age > 75 years All  Admission rate %.  
In-hospital outcomes.      
Adherence to guidelines when 
relevant. 
  
2. Female gender All 
3. Killip 3 and 4 at admission All 
4. Charlson Comorbidities Index (CCI) ≥ 2 All 
5. Diabetes All 
6. Renal insufficiency moderate & severe All 
7. Basic insurance coverage only All 
* Eligible patients: denominator of the ratio for adherence to guidelines calculation, or for admission rate. AMI: acute myocardial infarction; AC: anticoagulant 
therapies; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: aspirin; CCI: weighted Charlson index for comorbidities; 
DAPT: dual antiplatelet therapy; IQR: interquartile range; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; MACCE: major 
adverse cardiac- and cerebrovascular events; NSTEMI AMI without ST elevation on the initial electrocardiogram; P2Y12 indirect (thienopyridines) and direct 
P2Y12 inhibitors; (P) PCI (primary) percutaneous coronary intervention; STEMI AMI with segment ST-elevation or new left bundle branch block on the initial 
electrocardiogram 
 
Mortality and MACCE were adjusted for differences in base-
line characteristics known to influence survival and admis-
sion year. We used a logistic regression model with in-
hospital mortality (or MACCE) as a dependent variable and
the following independent variables: year of admission as
the variable of interest, and age, sex, resuscitation before
admission, diagnosis STEMI/NSTEMI, Killip class 3 or 4
at admission and comorbidities as characteristics known for
their strong impact on in-hospital mortality (heart failure,
diabetes, renal insufficiency or metastatic tumors) and thus
acting as potential confounders.[23] The odd ratios (ORs)
were presented with 95% CI. The SPSS software (SPSS Inc.,
Chicago, Illinois; Version 21.0) was used for all statistical
analyses.
3. RESULTS
The clinical registry enrolled 5,935 patients (2,491 in 2011,
2,544 in 2012) whose data were available at the registry data
center at the end of June 2013. The data were accessed and
controlled for our secondary analysis: 5,035 patients met
the study inclusion criteria and the remaining 900 patients
were excluded for the following reasons: double entries
(n = 142 patients transferred and included both in hospi-
tals with and without CathLab for the same AMI); patients
who had PCI before admission in a non-reporting hospital
(n = 92); patients from hospitals that did not participate
in both years of the registry (n = 666 in total, divided in
n = 450 for participation in 2011 only, n = 216 for participa-
tion in 2012 only).
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Table 3. Baseline characteristics of patients admitted with AMI according to year of admission
 
 
 
       2011 2012 p-value 
N patients (N hospitals) 2,491 (33) 2,544 (33)  
N patients (%) from hospitals with CathLab ( N  = 12) 1,834 (73.6) 1,981 (78.1)  
N patients (%) from hospitals without CathLab ( N = 21) 657 (26.4) 563 (21.9)  
Transfers from non-participating hospitals 610 (24.5) 636 (25.0)  
PPCI 1,760 (70.7) 1,840 (72.3)  .416 
Age (years)  67.1 ± 13.1  66.6 ± 13.0   .231 
Male gender 1,807 (72.5) 1,883 (74.0)  .237 
Delay symptoms onset to admission  1,667 1,808  
    • hours: minutes (median, IQR 25, 75 quartiles) 3:30 (1:37, 8:45) 3:06 (1:30, 8:30)  .264 
Diagnosis STEMI 1,295 (52.0) 1,320 (51.9)  .943 
Resuscitation prior admission 123 (4.9) 153 (6.0)  .093 
Symptoms at admission: typical 2,035 (81.7) 2,000 (78.6)  .022 
Vital signs at admission:    
    • Systolic blood pressure < 100 mmHg  145 (5.9) 182 (7.3)  .051 
    • Heart rate > 100 beats  269 (11.0) 240 (9.6)  .125 
Heart rhythm:    
    • Sinus rhythm  2,236 (89.8) 2,303 (90.5)  .666 
    • Atrial fibrillation  133 (5.3) 137 (5.4)  
Killip class:  2,483 2,535  .866 
    • 1  2,032 (81.8) 2,085 (82.2)  
    • 2 238 (9.6) 247 (9.7)  
    • 3 83 (3.3) 75 (3.0)  
    • 4  130 (5.2) 128 (5.1)  
Risk factors:    
    • Current smoker 855 (38.4) 872 (38.5)  .904 
    • History of Dyslipidemia  1,195 (54.3) 1,355 (58.9)  .002 
    • History of Hypertension  1,518 (64.2) 1,519 (62.2)  .160 
    • History of Diabetes  506 (21.4) 501 (20.3)  .341 
    • Obesity Body Mass Index > 30 465 (22.4) 477 (21.5)  .465 
History of MI or stable angina 830 (34.3) 812 (32.8)  .275 
Vulnerable sub-groups:    
    • Age > 75 years 795 (31.9) 758 (29.8)  .104 
    • Female gender  684 (27.5) 661 (26.0)  .237 
    • Killip classes 3 and 4 at admission 213 (8.6) 203 (8.0)  .464 
    • Diabetes (patient history) 506 (21.4) 501 (20.3)  .341 
    • Renal insufficiency 224 (9.2) 230 (9.2)  .990 
    • CCI  ≥ 2 627 (25.2) 645 (25.4)  .881 
    • Basic insurance coverage only 1,693 (71.6) 1,859 (75.4)  .003 
Note. Values are mean ± SD (standard deviation), median (IQR), N/total (%), or N. MI: (acute) myocardial infarction; CathLab a round the clock catheter 
laboratory service available; CCI: Charlson index for comorbidities; IQR: interquartile range; PPCI: primary percutaneous coronary intervention; NSTEMI 
AMI without ST elevation on the initial electrocardiogram; STEMI AMI with segment ST-elevation or new left bundle branch block on the initial 
electrocardiogram  
As shown in Table 3, patient baseline characteristics such as
age, gender, AMI diagnosis, hemodynamic status at entry,
major risk factors, and degree of comorbidities measured
by the Charlson index were not statistically significantly dif-
ferent between the 2 years of admission; however, a higher
number of patients with “basic insurance coverage only” was
recorded in 2012.
The results showed no statistically significant differences
in the quality of treatment for eight indicators of adherence
to evidence-based recommendations. The indicators 1 and
4 could not appropriately record the prescription of a new
direct P2Y12 inhibitor treatment introduced onto the market
at the end of 2011; the registry questionnaire was modified in
October 2011 to collect this new item but the changes were
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implemented at an unequal pace amongst hospitals; there-
fore, the observed difference between 2011 and 2012 cannot
be taken into consideration statistically nor clinically (see
Table 4).
Overall, the adjusted rates of mortality (OR 1.061, 95% CI
0.784-1.435) and MACCE (OR 0.915, 95% CI 0.704-1.188)
did not show statistically significant changes in 2012 vs.
2011. There was a statistically significant reduction of 1 day
in the median LOS in 2012 compared to 2011, in all patients
and in STEMI patients (median of 5 days [IQR 2,8] in 2011
to 4 days [IQR 2,7] in 2012, p = .001); vulnerable subgroups
were not discharged earlier.
The analyses of the seven vulnerable subgroups showed that
one subgroup, the patients with Killip class 3 or 4 at admis-
sion, had statistically significant worse in-hospital outcomes.
After adjustment for age and gender, the results confirmed
that year of admission had influenced in-hospital mortality in
these patients (OR 1.60, 95% CI 1.06-2.41) and in-hospital
MACCE (OR 0.658, 95% CI 0.439-0.987).
Table 4. Impact of admission year on adherence rate to evidence-based recommendations in AMI patients
 
 
Adherence rate to evidence-based recommendations in % (N) 2011 2012 p-value 
1. Immediate triple therapy (ASA, P2Y12, AC) 86.6 (1,774) 75.7 (1,875) < .001* 
2. Primary PCI performed: PPCI 73.2 (1,730) 74.8 (1,797)  .402 
3. Evaluation of LVEF  84.2 (1,991) 85.1 (2,043)  .406 
4. DAPT  (ASA, P2Y12) at discharge 93.7 (2,041) 87.0 (2,079) < .001* 
5. Beta-blocker at discharge 74.2 (1,731) 72.1 (1,730)  .096 
6. Statins at discharge 88.9 (2,079) 89.5 (2,149)  .466 
7. ACEI or ARB for LVSD, at discharge 85.7 (654) 85.9 (639)  .923 
8. Cardiac rehabilitation patient referral 43.7 (750) 45.3 (786)  .330 
9. Door-to-balloon time ≤ 90 minutes 62.1 (347) 65.3 (416)  .246 
10. Time to reperfusion ≤ 12 hours 83.9 (390) 85.2 (459)  .574 
* The differences in the indicators 1 and 4 are due to the introduction of a new antiplatelet drug at the end of 2011. No weighted adjustment was statistically 
possible for the 33 hospitals. AMI: acute myocardial infarction; AC :anticoagulant therapies; ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin 
receptor blocker; ASA: aspirin; DAPT: dual antiplatelet therapy; LVEF left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; P2Y12 
indirect (thienopyridines) and direct P2Y12 inhibitors; PCI: percutaneous coronary intervention 
 
 
 
 
4. DISCUSSION
The customized use of clinical registry data enabled a clinical
assessment of hospital treatment quality independent from
administrative data and SwissDRGs. Despite the limited
time available for our research before the introduction of the
reform, it was possible to collect prospective data before the
hospital payment changes and to perform a before and after
observational study.
4.1 Comments on the results
The 33 study hospitals were distributed across Switzerland
and represented about 30% of all AMIs.[24] The higher num-
ber of patients with “basic insurance cover only” in 2012
could be a simple consequence of a reclassification of pa-
tients following the new hospital planning. Baseline charac-
teristics in 2011 and 2012 confirmed the absence of relevant
differences in the clinical profile of the two populations in
comparison.
The results showed that the quality of treatment for AMI
patients was maintained overall after the introduction of new
policies and SwissDRGs. However, this finding needs to be
interpreted cautiously. First, it is not clear how the clinical
team has achieved this preservation of quality and whether
this result will hold over time. Additional studies, which
focus on the behavior of healthcare professionals, would be
useful to help interpret these results because both medical and
non-medical staff are key players for implementing evidence-
based recommendations.[25] Moral distress could develop
following challenging or constraining conditions of work.[26]
This is all the more important, as a recent mixed-method
study emphasized the importance of an integrated approach
to quality management.[27] Concerning the reduction of the
LOS, it is recognized that LOS influences substantially total
hospital expenses.[28] Nevertheless, if this result is confirmed
over time, it still has to be interpreted with prudence as a pos-
itive impact because waste may not have been reduced, rather
it could just represent a shift of activities to the ambulatory
sector without any overall cost reduction. The EuroDRG
group, who identified the difficulty to match AMI clinical
patterns with an appropriate DRGs classification for costs
and performance comparison, has already recognized this
issue.[29]
With regard to the subgroup of patients with Killip class 3 or
4 at admission, their worse in-hospital mortality could reflect
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a stochastic variation, but also the emergence of difficulties
for clinical teams to cope with patients demanding extra care
and time under cost constraints. Even an incorrectly per-
ceived loss of quality by clinical teams has been associated
with an increase of patient mortality.[30]
It is interesting to note that the analysis of specific clusters
for vulnerable patients has detected changes that would have
remained invisible in a solely global quality appraisal. It has
already been demonstrated that global health outcomes can
mask differences between groups and in particular for the
ones vulnerable to inequalities.[31] The DRGs system itself
favors a global approach because variations from a standard
case are regarded as outliers to be solved by a continuous
adjustment. Our study shows that health care quality could
be impaired for one vulnerable group. This quality issue is
also implicitly recognized at the European level as payment
incentives for quality are recommended in order to improve
the DRGs system.[32]
4.2 Comments on the study process
The pioneer aspect in Switzerland of this study is explained
by the following factors. First, the absence of a single health
insurance provider as well as the legislation on privacy and
data protection has limited the development of nationally
publicly funded clinical registries. Second, there is as yet
no single center for quality and safety of the Swiss health
care system; the Swiss Federal Council is currently working
on a federal law for such a center. The Swiss Academy of
Medical Sciences has been consulted and has emphasized the
issues of governance and independence as well as the need
for high quality medical registries and measurements.[33]
On a more general point of view, the governance and inde-
pendence of hospital quality evaluation remain important
issues. This applies not only to the Swiss Bismarck model of
hospital care, but also to countries with a Beveridge model
of national healthcare systems, which may have more exten-
sively developed medical databases for quality evaluation
but are also heavily dependent on public funding. An inde-
pendent evaluation of health care quality would support the
learning process regarding clinical practice under cost pres-
sures, and encourage the “bottom-up” involvement of clinical
teams in discussions pertaining to health care policies.
4.3 Limitations
This study has some limitations. First, the main limit came
from the time-limited funding of the project, which did not
permit pursuing the monitoring after 2013. A prolongation
would increase the chance to detect changes in treatment if
they occur. Second, the advantage of ready-to-use secondary
data was counterbalanced by the dependence on the underly-
ing clinical registry’s unalterable structure. Clinical registries
carry a risk of bias through non-consecutive inclusion and
confounding factors. The quality of the data recording, the
need to include consecutive patients, the necessity of long-
term commitment from the participating hospitals and the
conduct of regular audits are key elements of registry use-
fulness. A further limitation came from the impossibility
to introduce in this short time period the collection of con-
traindications to- or patient refusal of- drug treatment, as
well as the collection of controlled high-technology data (for
instance number and type of stents), patient socio-economic
indicators, or satisfaction scales for patients and clinical
teams. These limitations identify how challenging it can be
to involve clinical registries in quality assessment research.
They also indicate directions for improvement such as the
implementation of recommendations to promote the quality
and social value of clinical registries, and the importance to
maintain a good interdisciplinary dialogue for an indepen-
dent evaluation of hospital quality.
4.4 Ethical perspective
The interface between established clinical registries and qual-
ity assessment research projects also raises some ethical
points of consideration.
Firstly, data ownership and funding can become an issue
in the cooperation process, for instance between publicly
founded academic projects and privately funded registries.
Sustainable funding is a real issue for clinical registries, and
fees for data could stimulate fruitful collaboration on health
care quality improvement projects.[34] However, this could
also lead to moral and legal issues of data ownership, which
need to be further explored.
Secondly, data sharing and trust can be difficult to appropri-
ately manage. Secondary analysis of registry data has been
reported to be useful to improve patient care, but the absence
of a centralized shared repository of data is regarded as a
barrier to its development.[35]
Thirdly, confidentiality, consent and patient information are
important points to be discussed. According to the Swiss
law for human research, ethical review committees waived
patient informed consent for most of the registries dealing
with anonymous data.[36] Consequently, patients are usually
not informed of the possible secondary use of their data for
research projects on health care quality and access to care.
This may not be a problem as long as there is a clear benefit
from the research on health care quality. However, an ethical
issue with patient information would emerge more clearly if
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the quality of health care services worsens, or if some groups
of patients are stigmatized because they demand more care
and thus cost more than the average patient. Better infor-
mation to patients could help improve transparency in the
production and use of data and increase patient’s knowledge
and agency. As a result, the production and use of observa-
tional data could strengthen trustful relationships between
health care providers and patients.[37]
5. CONCLUSION
Sharing of observational clinical data allowed the realization
of this before and after study in order to perform an inde-
pendent assessment of the impact of new hospital financial
policies on the quality of hospital treatment. In the first year
following the introduction of the reform, the study showed
a reduction of the LOS for AMI patients, but no significant
modification of the evidence-based treatment delivered to
them. The specific measurements of outcomes in pre-defined
sub-groups of patients identified one group, namely those
with AMI related cardiac insufficiency at admission, who
demonstrated a higher risk of in-hospital complications and
mortality between the before and after phases. These findings
need to be confirmed over a longer period of time, but can
already contribute to the discussion about hospital costs, pro-
fessional practice constraints, quality of healthcare services
and their concomitant evaluation.
Ethical approval
AMIS Plus Registry had ethical approval from the Supra-
Regional Ethics Committee for Clinical Studies, the Swiss
Board for Data Security, and the Cantonal Ethics Com-
missions. Trial registration: ClinicalTrials.gov (identifier
NCT01305785).
ACKNOWLEDGEMENTS
All the authors contributed to the study and have read and
approved the final version of the manuscript. CMD car-
ried out the study design, the data analysis, and drafted the
manuscript. NBA provided advice during the study, helped
conceptualize the presentation of the research results, and
reviewed the manuscript. MAP supervised the data analysis,
helped organize the manuscript and reviewed it.
The authors thank the AMIS Plus registry, the participat-
ing hospitals and the AMIS Plus Data Center in Zurich.
Data were provided by AMIS Plus registry free of charge.
The authors thank Prof. Thomas Zeltner who reviewed the
manuscript for the legal aspects of the Swiss hospital fi-
nancing system described in the introduction and Table 1.
CMD was supported by a grant from the Swiss National
Science Foundation SNSF in relation to the IDoC project
(SNF RSII3_132786).
CONFLICTS OF INTEREST DISCLOSURE
The authors declare that they have no competing interests.
REFERENCES
[1] Federal Health Insurance Act of 18 March 1994 (Status as of 1 July
2013): SR 832.10. 1. Message 04.061 about the partial revision
of the Federal Health Insurance Act (hospital financing): BBI
2001 5551. OECD Reviews of Health Systems: Switzerland 2011.
Available from: http://www.oecd-ilibrary.org/social-i
ssues-migration-health/oecd-reviews-of-health-sys
tems-switzerland-2011_9789264120914-en
[2] Wild V, Pfister E, Biller-Andorno N. Ethical research on the imple-
mentation of DRGs in Switzerland – a challenging project. Swiss
Med Wkly. 2012. http://dx.doi:10.4414/smw.2012.13610
[3] Arah OA. On the evaluative space for measuring public health perfor-
mance. The philosophy of public health. Dawson A editor. England:
Farnham; 2009. 49-62 p.
[4] Hernandez AF, Fonarow GC, Liang L, et al. The need for multi-
ple measures of hospital quality. Results from the Get With The
Guidelines–Heart failure registry of the American heart association.
Circulation. 2011; 124: 712-719. http://dx.doi.org/10.1161
/circulationaha.111.026088
[5] Federal Office of Public Health. Topics / Health Insurance: Qual-
ity indicators in hospital statistics [cited 2013 Dec 9]. Available
from: http://www.bag-anw.admin.ch/kuv/spitalstatisti
k/portal_de.php?navid=qiss
[6] Busse R, Nimptsch U, Mansky T. Measuring, monitoring, and man-
aging quality in Germany’s hospitals. Health Aff (Millwood). 2009;
28(2): 294-304. http://dx.doi.org/10.1377/hlthaff.28.2.
w294
[7] Sheikh A, Atun R, Bates DW. The need for independent evaluations
of government-led health information technology initiatives. BMJ
Qual Saf. 2014; 23: 611-613. http://dx.doi.org/10.1136/bmj
qs-2014-003273
[8] Nichols M, Townsend N, Luengo-Fernandez R, et al. Eu-
ropean Cardiovascular Disease Statistics 2012. European
Heart Network, Brussels, European Society of Cardiol-
ogy, Sophia Antipolis [cited 2013 Dec 9]. Available from:
http://www.escardio.org/about/documents/eu-cardiov
ascular-disease-statistics-2012.pdf
[9] Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008
performance measures for adults with ST-elevation and non–ST-
elevation myocardial infarction. J Am Coll Cardiol. 2008; 52: 2046-
2099. http://dx.doi.org/10.1016/j.jacc.2008.10.012
[10] Jernberg T, Johanson P, Held C, et al. Association between adop-
tion of evidence-based treatment and survival for patients with ST-
elevation myocardial infarction. JAMA. 2011; 305(16): 1677-1684.
http://dx.doi.org/10.1001/jama.2011.522
[11] Gliklich RE, Dreyer NA. Registries for Evaluating Patient Outcomes:
A User’s Guide. Agency for Healthcare Research and Quality (US).
18 ISSN 1927-6990 E-ISSN 1927-7008
http://www.sciedupress.com/jha Journal of Hospital Administration 2016, Vol. 5, No. 3
Second edition. Rockville, MD; 2010 [cited 2013 Dec 9]. Available
from: http://www.effectivehealthcare.ahrq.gov/index
.cfm/search-for-guides-reviews-and-reports/?pageac
tion=displayproduct&productid=401
[12] Radovanovic D, Nallamothu BK, Seifert B, et al. Temporal trends
in treatment of ST-elevation myocardial infarction among men and
women in Switzerland between 1997 and 2011. Eur Heart J Acute
Cardiovasc Care. 2012; 1(3): 183-191.
[13] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines
for the management of patients with ST-elevation myocardial infarc-
tion. Executive summary. J Am Coll Cardiol. 2004; 110: 588-636. ht
tp://dx.doi.org/10.1161/01.CIR.0000134791.68010.FA
[14] Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of
the ACC/AHA 2004 guidelines for the management of patients with
ST-elevation myocardial infarction. Circulation. 2008; 117: 296-329.
http://dx.doi.org/10.1016/j.jacc.2007.10.001
[15] Van de Werf F, Bax J, Betriu A, et al. Management of acute my-
ocardial infarction in patients presenting with persistent ST-segment
elevation. Eur Heart J. 2008; 29: 2909-2945. http://dx.doi.org
/10.1093/eurheartj/ehn416
[16] Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guide-
lines for the management of patients with unstable angina/non–ST-
elevation myocardial infarction: Executive summary. Circulation.
2007; 116: 803-877. http://dx.doi.org/10.1161/CIRCULATI
ONAHA.107.185752
[17] Wijns W, Kohl P, Danchin N, et al. Guidelines on myocardial revas-
cularization. Eur Heart J. 2010; 31: 2501-2555. http://dx.doi.o
rg/10.1093/eurheartj/ehq277
[18] Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA
focused update of the guidelines for the management of patients
with unstable angina/non–ST-elevation myocardial infarction (up-
dating the 2007 guideline). Circulation. 2011; 123: 2022-2060.
http://dx.doi.org/10.1161/CIR.0b013e31820f2f3e
[19] Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the man-
agement of acute coronary syndromes in patients presenting without
persistent ST-segment elevation. Eur Heart J. 2011; 32: 2999-3054.
http://dx.doi.org/10.1093/eurheartj/ehr236
[20] Gharacholou SM, Lopes RD, Alexander KP, et al. Age and out-
comes in ST-segment elevation myocardial infarction treated with
primary percutaneous coronary intervention: findings from the
APEX-AMI trial. Arch Intern Med. 2011; 171(6): 559-67. http:
//dx.doi.org/10.1001/archinternmed.2011.36
[21] D’Ascenzo F, Gonella A, Quadri G, et al. Comparison of mortal-
ity rates in women versus men presenting with ST-segment ele-
vation myocardial infarction. Am J Cardiol. 2011; 107: 651-654.
http://dx.doi.org/10.1016/j.amjcard.2010.10.038
[22] Mercado-Martínez J, Rivera-Fernández R, Aguilar-Alonso E, et
al. APACHE-II score and Killip class for patients with acute my-
ocardial infarction. Intensive Care Med. 2010; 36(9): 1579-1586.
http://dx.doi.org/10.1007/s00134-010-1832-6
[23] Radovanovic D, Seifert B, Urban P, et al. Validity of Charlson Comor-
bidity index in patients hospitalised with acute coronary syndrome.
Insights from the nationwide AMIS Plus registry 2002-2012. Heart.
2014; 100(4): 288-294. http://dx.doi:10.1136/heartjnl-2
013-304588
[24] Insam C, Paccaud F, Marques-Vidal P. Trends in hospital discharges,
management and in-hospital mortality from acute myocardial infarc-
tion in Switzerland between 1998 and 2008. BMC Public Health.
2013; 13: 270-283. http://dx.doi.org/10.1186/1471-245
8-13-270
[25] Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST
elevation acute myocardial infarction in Europe: description of the
current situation in 30 countries. Eur Heart J. 2010; 31: 943-957.
http://dx.doi.org/10.1093/eurheartj/ehp492
[26] Fourie C. Moral Distress and Moral Conflict in Clinical Ethics.
Bioethics Published Online First: 8 November 2013. http://dx
.doi.org/10.1111/bioe.12064
[27] Wagner C, Groene O, Thompson CA, et al. DUQuE quality manage-
ment measures: associations between quality management at hospital
and pathway levels. Int J Qual Health Care. 2014 Apr; 26(Suppl 1):
66-73. http://dx.doi.org/10.1093/intqhc/mzu020
[28] Felder S. The variance of length of stay and the optimal DRG out-
lier payments. Int J Health Care Finance Econ. 2009; 9: 279-289.
http://dx.doi.org/10.1007/s10754-008-9051-1
[29] Quentin W, Rätto H, Peltola M, et al. Acute myocardial infarction
and diagnosis-related groups: patient classification and hospital re-
imbursement in 11 European countries. Eur Heart J. 2013; 34: 1972-
1981. http://dx.doi.org/10.1093/eurheartj/ehs482
[30] Tvedt C, Sjetne IS, Helgeland J, et al. An observational study: associ-
ations between nurse-reported hospital characteristics and estimated
30-day survival probabilities. BMJ Qual Saf. 2014; 23(9): 757-64.
http://dx.doi.org/10.1136/bmjqs-2013-002781
[31] Petticrew M, Whitehead M, Macintyre J, et al. Evidence for public
health policy on inequalities: 1: The reality according to policy-
makers. J Epidemiol Community Health. 2004; 58: 811-816. PMid:
15365104. http://dx.doi.org/10.1136/jech.2003.015289
[32] Busse R, Geissler A, Aaviksoo A, et al. Diagnosis related groups
in Europe: moving towards transparency, efficiency, and quality in
hospitals? BMJ. 2013; 346: f3197. http://dx.doi.org/10.11
36/bmj.f3197
[33] Statement of the Swiss Academy of Medical Sciences, in German,
dated September 5, 2014. Akademien äussern sich kritisch zum Bun-
desgesetz über ein Zentrum für Qualität in der OKP [cited 2014
Sep 8]. Available from: http://www.samw.ch/de/Aktuell/New
s.html
[34] Bufalino VJ, Masoudi FA, Stranne SK, et al. The American Heart
Association’s Recommendations for Expanding the Applications of
Existing and Future Clinical Registries: A Policy Statement From the
American Heart Association. Circulation. 2011; 123(19): 2167-2179.
http://dx.doi.org/10.1161/CIR.0b013e3182181529
[35] Cooke CR, Iwashyna TJ. Using existing data to address important
clinical questions in critical care. Crit Care Med. 2013; 41(3): 886-
896. http://dx.doi.org/10.1097/CCM.0b013e31827bfc3c
[36] Federal Human research Act of 30 September 2011 (status as of 1
January 2014): SR 810.30.
[37] Ioannidis JP. Informed Consent, Big Data, and the Oxymoron of
Research That Is Not Research. Am J Bioeth. 2013; 13/4: 40-42.
http://dx.doi.org/10.1080/15265161.2013.768864
Published by Sciedu Press 19
